BridgeBio Pharma BBIO) stock received a Perform rating from Oppenheimer on market challenges to its late-stage assets acoramidis and infigratinib. Read more here.
During the meeting Hyderabad CP explained to the gathering about the difficulties faced by not only various government departments but also the general public due to the uncontrolled use of DJ Systems ...